Long term outcomes of stereotactic body radiation therapy for hepatocellular carcinoma without macrovascular invasion.

[1]  K. Chiu,et al.  Combined Stereotactic Body Radiotherapy and Checkpoint Inhibition in Unresectable Hepatocellular Carcinoma: A Potential Synergistic Treatment Strategy , 2019, Front. Oncol..

[2]  C. N. Coleman,et al.  Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma. , 2019, Cancer research.

[3]  Michael Lock,et al.  Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial , 2019, The Lancet.

[4]  S. Vinod,et al.  Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial. , 2019, The Lancet. Oncology.

[5]  P. Schirmacher,et al.  EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. , 2018, Journal of hepatology.

[6]  P. Galle,et al.  IMbrave150: A randomized phase III study of 1L atezolizumab plus bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma. , 2018 .

[7]  Adam Johansson,et al.  Modeling of Normal Tissue Complications Using Imaging and Biomarkers After Radiation Therapy for Hepatocellular Carcinoma. , 2018, International journal of radiation oncology, biology, physics.

[8]  L. Dawson,et al.  Advances in Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma. , 2017, Seminars in radiation oncology.

[9]  L. Dawson,et al.  Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis. , 2017, Journal of hepatology.

[10]  Joe Y. Chang,et al.  Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells , 2016, Clinical Cancer Research.

[11]  Lipika Goyal,et al.  Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  E. Kunieda,et al.  Phase 2 study of stereotactic body radiotherapy and optional transarterial chemoembolization for solitary hepatocellular carcinoma not amenable to resection and radiofrequency ablation , 2016, Cancer.

[13]  Erich P Huang,et al.  RECIST 1.1-Update and clarification: From the RECIST committee. , 2016, European journal of cancer.

[14]  L. Dawson,et al.  Predictors of Liver Toxicity Following Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma. , 2015, International journal of radiation oncology, biology, physics.

[15]  S. Fu,et al.  Charged particle therapy versus photon therapy for patients with hepatocellular carcinoma: a systematic review and meta-analysis. , 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[16]  L. Dawson,et al.  Outcomes following definitive stereotactic body radiotherapy for patients with Child-Pugh B or C hepatocellular carcinoma. , 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[17]  E. Kunieda,et al.  Stereotactic body radiotherapy for small hepatocellular carcinoma: A retrospective outcome analysis in 185 patients , 2014, Acta oncologica.

[18]  Jong Hoon Kim,et al.  Stereotactic Body Radiation Therapy as an Alternative Treatment for Small Hepatocellular Carcinoma , 2013, PloS one.

[19]  P. Bie,et al.  Radiofrequency ablation versus hepatic resection for the treatment of early-stage hepatocellular carcinoma meeting Milan criteria: a systematic review and meta-analysis , 2013, World Journal of Surgical Oncology.

[20]  Zahra Kassam,et al.  Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Minshan Chen,et al.  Recurrent hepatocellular carcinoma treated with sequential transcatheter arterial chemoembolization and RF ablation versus RF ablation alone: a prospective randomized trial. , 2012, Radiology.

[22]  T. Goto,et al.  nature publishing group ORIGINAL CONTRIBUTIONS 569 CME Radiofrequency Ablation for Hepatocellular Carcinoma: 10-Year Outcome and Prognostic Factors LIVER , 2022 .

[23]  J. Marrero,et al.  NCCN clinical practice guidelines in oncology: hepatobiliary cancers. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

[24]  Byung Chul Yoo,et al.  Percutaneous Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma After Hepatectomy: Long-term Results and Prognostic Factors , 2007, Annals of Surgical Oncology.

[25]  Ramon Planas,et al.  Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial , 2002, The Lancet.

[26]  J. Bruix,et al.  Intention‐to‐treat analysis of surgical treatment for early hepatocellular carcinoma: Resection versus transplantation , 1999, Hepatology.

[27]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[28]  R. T. Ten Haken,et al.  Individualized Adaptive Stereotactic Body Radiotherapy for Liver Tumors in Patients at High Risk for Liver Damage: A Phase 2 Clinical Trial , 2018, JAMA oncology.

[29]  Riccardo Lencioni,et al.  EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. , 2012, Journal of hepatology.